Monitor for upcoming funding announcements or partnerships, as the company will need substantial capital before late 2026. The recent dilutive offering combined with declining cash suggests near-term financing risk despite clinical progress.
Price Chart
Executive Summary
Lantern Pharma reported Q4 2025 earnings with net loss per share of $-0.36, in-line with consensus, and highlighted clinical progress including FDA IND clearance for its pediatric CNS cancer program and Orphan Drug Designation for LP-284. However, cash reserves declined to $10.1 million, triggering a recent capital raise and raising concerns about runway and funding needs.
Key Financial Metrics
Key Facts
- Net loss per share of $-0.36 for Q4 2025, in-line with analyst consensus
- Cash, cash equivalents, and marketable securities declined to $10.1 million as of December 31, 2025, down from $24.0 million a year prior
- FDA cleared IND for Starlight Therapeutics' planned Phase 1 pediatric CNS cancer trial of STAR-001
- LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas
- Company believes existing cash will fund operations until late July to mid-September 2026, but will need substantial additional funding
- Recent best-efforts common stock offering filed within 30 days of earnings, indicating potential financial pressure
Financial Impact
Cash position down 58% YoY to $10.1 million, with net loss of $4.1M in Q4
Risk Factors
- Insufficient cash runway requiring dilutive financing
- Clinical trial setbacks could further pressure valuation
- Failure to secure additional funding could impact operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-013608 |
| Document: form8-k.htm | 0001493152-26-013608 |
| Document: 0001493152-26-013608-index-headers.html | 0001493152-26-013608 |
| Document: 0001493152-26-013608-index.html | 0001493152-26-013608 |
| Document: 0001493152-26-013608.txt | 0001493152-26-013608 |
| 8-K Data (Synthetic) | 0001493152-26-013608 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6240 (+4.94%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6240 (−12.20%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6240 (+27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6240 (+37.60%) |
Sep 30, 2026 26d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6240 (+38.22%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6240 (−48.43%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6240 (−55.11%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6240 (−76.45%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6240 (+83.92%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6240 (−79.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers